CERo Therapeutics Holdings, Inc. · OTC:CERO
CERo Therapeutics — Investor Presentation (April 2025)
23 slides from CERo Therapeutics's investor presentation, Apr 25, 2025
Slide 1: Investor Presentation April 2025
INVESTOR PRESENTATION April 2025 NASDAQ: CERO
Slide 2: Disclaimer
This presentation (this “Presentation”) is provided for informational purposes only and for no other purpose and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in CERo Therapeutics Holdings, Inc . (“CERo”) . The information contai
Slide 3: A Simple Idea Became a Novel, Powerful Therapeutic
A Simple Idea Became a Novel, Powerful Therapeutic Engineering Engulfment into TCells 3
Slide 4: Investment Highlights
Investment Highlights NASDAQ: CERO 4 • Novel Mechanism of Action (MOA) and Strong Scientific Rationale - Novel Chimeric Engulfment Receptor T cells (CER - T) platform redirects patient - derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms - Propri
Slide 5: Designed with the Best Parts of the Immune System
Designed with the Best Parts of the Immune System – T - Cells and Macrophages • Home to target cells • Rapidly multiply at site of target cells (tumor) • Punch holes in target cells • Signal rest of immune system • Form molecular memory , and persist • Eat (Phagocytosis) targeted tumor cells • Proce
Slide 6: What is a CER-T Cell?
What is a CER - T Cell? himeric ngulfment eceptor C E R Uses TIM - 4 Phagocytic Receptor to Engage Tumor Targets via the Cell of Damaged Receptor TIM - 4 Ligand Tumor Cell TIM 4 Ligand Tumor Cell CER - T Cell Multifunctional Construct Transmembrane Extracellular Domain Tumor binding and phagocytosis
Slide 7: CER-T Development Pipeline
CER - T Development Pipeline Pivotal Phase 2 / BLA Enabling Phase 2 Phase 1 Preclinical Development Indication AML Solid tumors – Ovarian Solid tumors – NSCLC NASDAQ: CERO 7
Slide 8: In Vivo Evidence of Anti-Tumor Killing
In Vivo Evidence of Anti - Tumor Killing A single infusion of CER - T cells specifically kills non - small cell lung cancer (NSCLC) cells EGFR - mutant NSCLC cells Single infusion of 2.5e^6 CER - 1236 T cells All animals (mice) received EGFR inhibitor therapy Robust anti - tumor in vivo responses ac
Slide 9: CER-T Cells Eliminate Mantle Cell Lymphoma Xenografts In Vivo
CER - T Cells Eliminate Mantle Cell Lymphoma Xenografts In Vivo A Single Infusion of CER - 1236 T Cells Eliminated TP53 mutant Mantle Cell Lymphoma tumors Single infusion of 2.5e^6 CER - 1236 T cells 0 40 10 5 10 4 10 6 10 7 10 8 10 9 10 10 20 Day post T cell infusion BLI (total photons/s SEM) No T,
Slide 10: Elimination of p53 Mutant AML Cell Lines in Mice
Elimination of p53 Mutant AML Cell Lines in Mice Dose Level I 5e^6 CER - 1236 T cells per mouse D + 50: 3 - log reduction in tumor No Treatment Untransduced T Cells CER - 1236 T Cells Day - 14 Kasumi - 1 Tumor inoculation 2e^6 cells/ mouse Day 0 Weekly BLI Measurements Weight PK Data Q Week T cell i
Slide 11: CER-1236 T Cells have not Shown Toxicity in Animal Tumor Models
CER - 1236 T Cells have not Shown Toxicity in Animal Tumor Models Single infusion of 7.5e^6 CER - 1236 T cells NO anemia, thrombocytopenia, neutropenia, or coagulation abnormalities NO weight loss, morbidity, unexpected mortality NO histological abnormalities across organs A Single Infusion of CER -
Slide 12: Robust Off-Target Safety Data
Robust Off - Target Safety Data No CER - 1236 T cell activation or cytotoxic T cell function observed against primary human cells representing central nervous system, heart, lungs, liver, GI tract, kidneys, spleen, or gonads. NO Off - target responses to primary human cells No T cell activation obse
Slide 13: Well-Positioned for Potential Phase I Success
Well - Positioned for Potential Phase I Success Deep preclinical data set showing promising efficacy and safety, novel mechanism of action, clinical history with CAR - T Adaptive Phase I designs in Relapsed and Refractory AML and solid tumors – early responses in Phase I may lead to accelerated clin
Slide 14: Significant Unmet Needs in AML
Significant Unmet Needs in AML • Relapsed/Refractory Subset – Allogeneic Hematopoietic Cell Transplant (HCT) is only curative option… – …but HCT is not an option if patient cannot achieve a Complete Response in prior therapy – Early Trial Endpoint: Complete Response (CR) • P53 – Subset – Patients al
Slide 15: Clinical Design – AML
Clinical Design – AML ~21 days NASDAQ: CERO 15
Slide 16: Clinical Design – Solid Tumor Study
Clinical Design – Solid Tumor Study NASDAQ: CERO 16
Slide 17: Unmatched Strategic Positioning
Unmatched Strategic Positioning Killing Capability T cells / Lymphocytes Macrophages / Monocytes Starting Cell Source Phagocytosis Lysis PHAGOCYTOSIS + LYSIS NASDAQ: CERO 17 PHAGOCYTOSIS
Slide 18: CERo Anticipated Timeline for 2025
CERo Anticipated Timeline for 2025 Q1 (2025) Q2 (2025) Q3 (2025) Q4 (2025) • First sites initiated • Orphan drug designation filed • Solid tumor IND filed and approved • Additional 2 - 3 patients dosed • Durability data from patient 1 • Investor conferences • First patient dosed • Additional sites i
Slide 19: Patent Portfolio Overview
• 9 Total Patent Families • 2 issued US patents – 1 patent covers genus of PtdSer targeting CERs with TLR signaling domain • Key patents with protection out to 2037 (EP), 2038 (CN and JP), and 2039 (US) • 17 issuances/allowances worldwide across patent families • Favorable ISR/WO * for CER1236 const
Slide 20: Management Team
• CEO, Launch One Acquisition Corp • Former CEO, Phoenix Biotech Acquisition Corp • Former CEO, Locust Walk Acquisition Corp • Former Senior Managing Director, Locust Walk • Former General Partner, Interwest Partners • Genentech, LEK Consulting • Adjunct Professor, University of San Francisco Chris
Slide 21: Board of Directors
• CEO, Launch One Acquisition Corp. • Former CEO, Phoenix Biotech Acquisition Corp • Former CEO, Locust Walk Acquisition Corp • Former Senior Managing Director, Locust Walk • Former General Partner, Interwest Partners • Genentech, LEK Consulting Chris Ehrlich Chief Executive Officer • CFO of FORE Th
Slide 22: The Next Era in Cancer Cell Therapy
The Next Era in Cancer Cell Therapy (NASDAQ: CERO) NOVEL APPROACH Powerful, multi - functional tumor clearing NEAR TERM VALUE Human data in 2025 PROVEN SUCCESS Experienced team, top investors, capital efficient LARGE OPPORTUNITY Target prevalent across many tumor types Designed and Engineered to be
Slide 23: Contact Details
Contact Details Investor & Media Relations: CORE IR Matt Blazei mattb@coreir.com Media Inquiries: CORE IR Jules Abraham julesa@coreir.com 23
CERo Therapeutics Holdings — Investor Presentation (April 2025) on 6ix